Indian stocks: Visit www.stage2stocks.com →

Monopar Therapeutics Inc.

Stage 3 · Topping · week 4

As of Oct 22, 2026, Monopar Therapeutics is in Stage 3, the topping phase, now in week 4 (since Oct 1, 2026). It closed at $72.58, 41.4% below its 52-week high and below its 200-day average, which is rising.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. More about the company

$72.58
+0.32% today
$487M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is MNPR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 26w
S2 30w
S2 21w
S3 13w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 26w → S1 5w → S2 8w → S3 4w → S2 8w → S3 4w → S4 2w → S2 30w → S3 3w → S2 4w → S3 6w → S2 21w → S3 13w → S4 7w → S1 8w → S2 12w → S3 3w current
Total tracked: 165 weeks across 17 stage runs.

MNPR among Biotechnology210th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…210MNPRStage 3 · wk 449−18.8%
vs 52W High
-41.4%
$50.12 lo$123.84 hi
41.4% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 4
1w13w26w
Week 4, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-5.8%
200 DMA: $77.06 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.72x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-18.8%
3M
-33.9%
6M
+36.3%
YTD
+10.0%
1Y
-6.5%
Scan Membership
Breakout Watch
Latest: 2025-05-16
6 appearances in last 60 days. First seen: 2021-02-10.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 4 · Vol 0.72x
2026-10-21S3
Wk 3 · Vol 0.53x
2026-10-20S3
Wk 3 · Vol 0.51x
2026-10-19S3
Wk 3 · Vol 0.39x
2026-10-16S3
Wk 3 · Vol 0.93x
2026-10-15S3
Wk 3 · Vol 0.80x
2026-10-14S3
Wk 2 · Vol 0.73x
2026-10-13S3
Wk 2 · Vol 1.38x
2026-10-12S3
Wk 2 · Vol 0.68x
2026-10-09S3
Wk 2 · Vol 0.71x
2026-10-08S3
Wk 2 · Vol 0.95x
2026-10-07S3
Wk 1 · Vol 0.53x
Moving averages & range
50 DMA
$96.38
200 DMA
$77.06
52W High
$123.84
52W Low
$50.12
5D Low
$69.27
Resistance levels (recent highs)
20d High
$85.24
60d High
$123.84
120d High
$123.84
250d High
$123.84
Next resistance
+17.4%
to 20d High
ROE
-19.5%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 3.7

Monopar Therapeutics: quick answers

What stage is Monopar Therapeutics in?

As of Oct 22, 2026, Monopar Therapeutics (MNPR) is in Stage 3, the topping phase. It entered Stage 3 on Oct 1, 2026 and is in week 4. What the four stages mean

Is Monopar Therapeutics in an uptrend?

Its uptrend has stalled. Monopar Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 5.8% below its 200-day average, which is rising.

How far is Monopar Therapeutics from its 52-week high?

Monopar Therapeutics closed at $72.58 on Oct 22, 2026, 41.4% below its 52-week high of $123.84. Its 52-week low is $50.12.

How has Monopar Therapeutics performed over the past year?

As of Oct 22, 2026, Monopar Therapeutics is down 6.5% over the past year and up 10.0% so far in 2026.

Which sector and industry is Monopar Therapeutics in?

Monopar Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.